Biden’s Visit Highlights China-U.S. Cooperation On API Oversight And Patent Protection
This article was originally published in PharmAsia News
Executive Summary
Last week, U.S. Vice President Joe Biden visited China, Japan, and South Korean during a six-day Asia trip. One of Biden’s goals in China was to strengthen collaboration between the two countries on food and drug safety as well as patent protection.
You may also be interested in...
FDA Inspection Growth In China Stymied By Visa Issues
The agency is waiting for approval to locate 10 new drug inspectors in China.
China One Step Closer To Global Standards For Drug Quality With Rollout Of New GMP Guidelines
SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China
U.S. FDA Launches First Overseas Office in Beijing
U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress